ACP-103

DRUG3 trials

Sponsors

National Institute of Neurological Disorders and Stroke (NINDS), ACADIA Pharmaceuticals Inc.

Conditions

DyskinesiasHallucinationsParkinson's DiseasePsychosesSchizophrenia

Phase 2

ACP-103 to Treat Parkinson's Disease

CompletedNCT00086294

National Institute of Neurological Disorders and Stroke (NINDS)Dyskinesias, Parkinson's Disease

Start: 2004-06-25End: 2007-11-15Target: 40Updated: 2017-07-02

Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug

CompletedNCT00087542

ACADIA Pharmaceuticals Inc.Hallucinations, Parkinson's Disease, Psychoses

Start: 2004-03-31End: 2005-12-31Target: 60Updated: 2005-12-07

Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone

CompletedNCT00361166

ACADIA Pharmaceuticals Inc.Schizophrenia

Start: 2005-08-31End: 2007-03-31Target: 400Updated: 2007-03-22